Faculty Chair Bureau

The ADVENT program is being developed in close collaboration with ADVENT Faculty Chair Bureau which consists of global experts in diseases with underlying type 2 inflammation.

The ADVENT Faculty Chair Bureau:

> Advise and validate the scientific content of the program
> Serve as faculty presenters at the ADVENT FORUM and other live events

Click the images to discover more about the members of the Dermatology Faculty Chair Bureau and the Respiratory Faculty Chair Bureau below:



Thomas Bieber

MD, PhD, MDRA, Professor
Chair, Department of Dermatology and Allergy

Christine Kühne–Center for Allergy Research and Education
University of Bonn, Germany

“ADVENT is an educational program bringing together different specialties treating patients with type 2 inflammatory diseases”

Prof. Thomas Bieber is professor and chair in the Department of Dermatology and Allergy at the University of Bonn, Germany. He is director of the Christine Kühne–Center for Allergy Research and Education. Prof. Bieber is also speaker of the Center for Translational Medicine, a collaborative program with the National Institute for Drug and Medical Devices (BfArM). He is honorary professor for dermatology at the Third Military Medical University of Chongqing, China.

Prof. Bieber received his degrees in medicine (MD) and biology (PhD) from the University of Louis Pasteur in Strasbourg, France. He then earned a master’s degree in drug regulatory affairs (MDRA), achieving special expertise in preclinical and clinical drug development.

In addition to clinical dermatology and allergy, Prof. Bieber’s scientific focus includes ontogeny and immunobiology of dendritic cells, specifically their role in atopic dermatitis (AD) and in tolerance mechanisms. He has special expertise in translational and precision medicine approaches for skin diseases.

Prof. Bieber has authored or coauthored more than 480 original publications and review articles and more than 100 book chapters. He has also authored or coauthored several books on AD and precision medicine. He was chief editor of Allergy, the official journal of the European Academy of Allergy and Clinical Immunology. He is a member of the German National Academy of Sciences.

Throughout his career, Prof. Bieber has received a number of honors: the distinguished Heisenberg Fellowship from the German Research Council, the Karl-Hansen-Award from the German Society of Allergy, the Pharmacia International Research Award, and the Gold Medal of the Foundation for Allergy Research in Europe. He has been invited to many distinguished lectureships, such as the Robert Cooke Memorial Lectureship by the American Academy of Allergy, Asthma and Immunology (USA), the international Dohi Memorial Lecture from the Japanese Society for Dermatology, the Bruno Bloch Memorial Lectureship from the University of Zürich (Switzerland), and the Karl Herxheimer Memorial Lectureship from the University of Frankfurt, Germany.


Emma Guttman-Yassky

The Department of Dermatology and the Icahn Immunology Institute at Mount Sinai – New York, NY

Dr Emma Guttman-Yassky, MD, PhD, is the Sol and Clara Kest Professor of Dermatology and Vice Chair for Research of the Department of Dermatology, Icahn School of Medicine at Mount Sinai Medical Center, New York, NY, where she directs the Center for Excellence in Eczema and the Laboratory of Inflammatory Skin Diseases. She completed her MD at Sackler Faculty of Medicine, Tel-Aviv; her PhD at Bar-Ilan University, Ramat Gan, Israel; and a dermatology residency at Weill Cornell, New York, NY. Dr Guttman-Yassky was awarded a postdoctoral fellowship at The Rockefeller University.

Dr Guttman’s current research interests are alopecia areata and atopic dermatitis, with a focus on multiple targeted therapeutics that target the Th2, Th22, and Th17/IL-23 axis. She has developed comprehensive molecular maps of atopic dermatitis, established the reversibility of its phenotype, and defined a series of biomarkers. Dr Guttman is lead author of textbook chapters and articles appearing in journals such as the Journal of Cutaneous Pathology and International Dermatology.

Dr Guttman is cofounder and president of the International Eczema Council. A recipient of multiple honors, she was elected to the American Society for Clinical Investigation and is a member of the American Dermatological Society, which honored her with the Young Investigator Award.


Norito Katoh

Professor and Chairperson, Department of Dermatology

Kyoto Prefectural University of Medicine, Japan.

Prof. Norito Katoh qualified in medicine in 1989 and gained a PhD in 1997. He has been a board certified dermatologist and allergist since 1995 and 2004, respectively. He had worked at the Immunobiology Laboratory, Department of Dermatology, University of Bonn, Germany, as a postdoctoral researcher in 1997-1998.

Prof. Katoh is Chairperson of the Executive Committee of Guidelines for the Management of Atopic Dermatitis of the Japanese Dermatological Association. He is a member of the Board of Directors of the International Society for Atopic Dermatitis, the Japanese Society for Investigative Dermatology, and many others. He is an editorial member of the Journal of Dermatological Science and the Journal of Dermatology.

Kari Nadeau


Dr Kari Nadeau is the Naddisy Foundation Endowed Professor of Pediatric Food Allergy, Immunology, and Asthma at Stanford University and the director of the Sean N. Parker Center for Allergy and Asthma Research at Stanford University. For more than 30 years, she has devoted herself to understanding how environmental and genetic factors affect the risk of developing allergies and asthma, and the molecular mechanisms underlying the diseases.

As one of the nation’s foremost experts in adult and pediatric allergy and asthma, her research is laying the groundwork for a variety of potential future therapies to prevent and cure allergies and asthma. She leads a diverse team of specialists — in areas from immunology to chemical engineering — a team that was among the first to show that high dimensional immunophenotyping of T cells involved in allergy could be used in therapies for patients. Her research has also shown that blocking antibodies in conjunction with allergen immunotherapy produced desensitization even in patients with up to five food allergens. She has overseen more than 40 clinical trials and enrolled more than 2,000 patients in allergy studies. Her work has changed the lives of many who, for the first time in their lives, are able to control life-threatening food allergies.

Dr Nadeau received her MD and PhD from Harvard Medical School. She completed a residency in pediatrics at Boston Children’s Hospital and a clinical fellowship in asthma and immunology at Stanford and at University of California, San Francisco. Her research and scientific breakthroughs have been covered in Lancet, JAMA, Nature Medicine, US News and World Report, New York Times, Discover, as well as other national and international media. Dr Nadeau has served as a White House Medical Consultant, a member of the Scientific Advisory Board of the EPA, NHLBI DSMB, NIH Study Sections, FARE Scientific Board, and a member of the American Lung Association Medical Board. She serves as the director of the Mechanism Committee for the American Academy of Allergy, Asthma and Immunology and is a member of ASCI (American Society of Clinical Investigation).

Jean-François Nicolas


Prof. Jean-François Nicolas is head of the Allergology and Clinical Immunology Department of Lyon University Hospital. He is a dermatologist, Professor of Immunology and PI of a research team in INSERM Unit 1111-CIRI (co-PI Marc Vocanson). The main research themes concern immunodermatology and more precisely the pathophysiology of skin inflammation.

Prof. Nicolas received his MD from Lyon University Medical School in 1983. His dermatology speciality degree was obtained through specific training in immunodermatology (Professor Jean Thivolet). He obtained a PhD in 1990, having trained at Scripps Clinic and the University of California, San-Diego (Dr Jacques Chiller) and having been a recipient of an INSERM young investigator award. He then entered INSERM as Research Director and worked successively in Dermatology (U 209 and U 346, 1990-1992) and Immunology (U80, U999 and U503, 1992-1998) Inserm Research Units.

Prof. Nicolas was appointed Professor of Immunology–Hospital Practitioner in 1998 in Lyon University Hospital where he developed a skin inflammation/drug allergy clinical unit that became in 2005 the Department of Allergology and Clinical Immunology (Co-Head Professor F Bérard). Scientific Summary.

Prof. Nicolas’s research activities concern the skin immune system, and especially the study of cellular and molecular signals that lead to immune responses or tolerance to cutaneous antigens and allergens. Research projects are directed at the understanding of the immune mechanisms leading to inflammatory skin diseases (eczemas, psoriasis and drug allergy) using both clinical, translational and fundamental studies in pre-clinical mouse models of these diseases. In addition, the team works on cutaneous routes of vaccination to improve the overall efficacy of vaccines. Important contributions include: i) the demonstration that CD8+ cytotoxic T cells are major effector cells of several antigen/allergen specific skin diseases including eczemas (allergic contact dermatitis and atopic eczema) and T cell-mediated drug allergies; ii) the characterization of different subsets of CD4+ Treg cells able to prevent (tolerance) or limit (regulation) the skin inflammation.

Prof. Nicolas is very much involved in the teaching/training of medical students, especially in the fields of allergy, skin biology, immunodermatology and clinical immunology. He has authored or co-authored over 150 research papers and book chapters. He is the Co-Editor of the European Journal of Dermatology that he founded with Jean Thivolet in 1990.

Amy Paller


Amy Paller, MD, MS is the Walter J. Hamlin Professor and Chair of the Department of Dermatology and Professor of Pediatrics at Northwestern University’s Feinberg School of Medicine, where she directs the NIH-funded Skin Disease Research Center. Dr Paller received her MD from Stanford University School of Medicine and completed a residency in pediatrics and dermatology at Northwestern University/the Ann and Robert H Lurie Children’s Hospital of Chicago. She was awarded a fellowship in dermatology at the University of North Carolina School of Medicine.

Dr Paller’s current research focus is discovering biomarkers associated with atopic dermatitis in children and generating and validating new tools for measuring patient-reported outcomes. She has directed the Pediatric Dermatology Clinical Trials Unit at Northwestern University/the Ann and Robert H. Lurie Children’s Hospital of Chicago for nearly 25 years, serving as lead investigator on several landmark trials for treating inflammatory skin disorders in children.

An author of more than 400 publications, Dr Paller is President of the International Eczema Council and the International Society for Pediatric Dermatology, and Vice President of the International Society for Atopic Dermatitis. She serves on the Council for the National Institute for Arthritis and Musculoskeletal and Skin Diseases. She co-authors Hurwitz Clinical Pediatric Dermatology and is an editor of the Journal of Investigative Dermatology. A recipient of multiple awards, Dr Paller’s recent honors include the Rothman Award from the Society for Investigative Dermatology and the Clarence S. Livingood, MD Memorial Award from the American Academy of Dermatology.

Kim Papp


Dr Kim Papp is a Member of the College of Physicians and Surgeons of Ontario, a Fellow of the Royal College of Physicians and Surgeons of Canada, and an American Board of Dermatology Diplomate. The Waterloo, Ontario, Canada based dermatologist has over 20 years’ experience as a Principal Investigator and has conducted over 130 psoriasis studies in which he closely supervised and assessed over 2750 subjects. Dr Papp is an internationally renowned Key Opinion Leader in psoriasis research who conducts clinical trials on a wide range of dermatological disorders. With the support of Probity Medical Research, an organization for which he serves as Founder and President, Dr Papp has earned the distinction of top enrolling investigator in over 70 international dermatology studies.

Dr Papp has conducted early through late phase psoriasis studies, and has been instrumental in the investigation and development of the following compounds: adalimumab (Humira®), AIN457, alefacept, AMG714, AMG827, apremilast (CC-10004), BIRB 796 BS, BIRT 2584XX, BMS-582949, briakinumab (ABT-874), CD 2027, clobex, CP-690,550, CRx-140, cyclosporine, dovobet, dovonex, efalizumab, etanercept, golimumab, ILV094, infliximab, KH 1650, MEDI-507, MEDI-545, methotrexate, onercept, recombinant human interleukin eleven (rhIL-11), roziglitazone maleate, RWJ-445380, tacrolimus, tazorac, tofacitinib (CP-690, 550), ustekinumab (CNTO1275), volclosporine (ISA247).

Papp Clinical Research, like many high-enrolling research sites, has had routine inspections by the Food and Drug Administration, Health Canada, and the European Medicines Agency. Dr Papp’s clinic has the unique distinction of producing no significant findings; the FDA’s Form 483—a standard document issued to non-compliant research centres—has never been issued to K. Papp Clinical Research.

Dr Papp has acted as consultant and/or advisor to over 40 pharmaceutical companies on the development of dermatological compounds. He is instrumental in improving and refining study designs, and serves on a number of Steering Committees and Advisory Boards tasked with developing effective and efficient strategies for the timely development of new treatments. An author on over 275 publications.

Carle Paul


Carle Paul is Professor and Chairman of the Department of Dermatology at Paul Sabatier University, Toulouse, France. The department has inpatient and outpatient clinics, a clinical research center (phase I to IV) and teaching facilities. A dedicated skin cancer unit has opened in 2014 in the Cancer University Institute of Toulouse. The department medical staff includes 14 full-time dermatologists, 10 residents and 10 part-time consultants.

Prof. Paul was appointed Lecturer in Dermatology and Director of the Clinical Pharmacology Unit in 1994–1997 at Saint Louis Hospital and Paris VII University. In 1998–2005, he worked in pharmaceutical research in Switzerland, while maintaining clinical appointment at the Department of Dermatology, Mulhouse, France. During this period he also worked on the development of dermatologic drugs, mainly for psoriasis, atopic dermatitis and fungal skin diseases. He contributed to the development of oral and topical calcineurin inhibitors for inflammatory skin diseases and allylamines antifungal agents. He was Board member of the European Academy of Dermatology and Venereology (EADV) from 2007 to 2012 and Secretary General (2012-2016). He is currently President-Elect of the EADV (2016-2018).

Prof. Paul is the co-inventor of 8 patents and the author of more than 350 peer-reviewed publications. His areas of research interest are inflammatory skin diseases, pharmacology and drug development.

Eric Simpson


Dr Eric Simpson practices medical dermatology, with special interests in chronic inflammatory skin diseases and skin cancer. He is actively involved in clinical research and is currently funded by the National Institutes of Health and industry partners to study new approaches to chronic skin disease treatment and prevention.

Dr Simpson’s collaborations are global in scope, and he has been invited to present his research and approach to patient care at international conferences in Europe, North and South America, and Asia. He has published over 80 scientific articles in several high-impact peer-reviewed journals, including The New England Journal of Medicine and The Lancet.

Dr Simpson supports patient advocacy by serving as the co-chair of the Scientific Advisory Committee for the National Eczema Association. He also serves on the Executive Committee of the Harmonizing Outcome Measures in Eczema (HOME)—a volunteer group of patients, providers, and other stakeholders whose mission is to improve the quality of eczema research to better suit the needs of patients and policy makers.

Outside of work, Dr Simpson enjoys spending time with his wife and children, playing squash, camping, hiking, fishing, and biking.


Koichiro Asano

Chief, Division of Pulmonary Medicine

Tokai University, Kanagawa, Japan

Dr Koichiro Asano graduated from the Keio University School of Medicine in Tokyo, Japan, where he completed his internship and residency. After his postdoctoral fellowship at Brigham and Women’s Hospital in Boston, Massachusetts, USA, under the supervision of Professor Jeffrey Drazen, he went back to Keio University, serving first as an assistant professor, then as an associate professor. In 2012, he became a professor and chief of the Division of Pulmonary Medicine at the Tokai University School of Medicine in Kanagawa.

Dr Asano’s research interests are the synthesis and functions of lipid mediators in the airways, innate immune response in the development of allergic airway diseases, including severe asthma, and fungus-associated allergic airway diseases.

Claus Bachert

University Hospital of Ghent, Belgium

Karolinska Institute, Stockholm, Sweden

Dr Claus Bachert is clinic chief and a professor at the University Hospital of Ghent, Belgium, as well as a professor at the Karolinska Institute, Stockholm, Sweden. In addition, he chairs the Upper Airways Research Laboratory at Ghent University. He qualified from the University of Heidelberg, Germany, and trained in ear, nose, and throat diseases and allergology in Mannheim and Düsseldorf.

Dr Bachert’s research interests include the pathophysiology and management of diseases of the nose and sinuses, such as allergic and nonallergic rhinitis, chronic rhinosinusitis, and nasal polyposis. Specifically, he has worked on endotyping rhinosinusitis, innovative treatments such as biologicals for recalcitrant disease, and the role of Staphylococcus aureus in inflammation in nasal polyp disease. Dr Bachert has published over 550 peer-reviewed articles in international journals and has been awarded several national and international prizes and 2 doctor honoris causa titles (Capital University, Beijing, China, and Democritus University, Thrace, Greece).

Dr Bachert has served as a member of the international guideline panels of Allergic Rhinitis and its Impact on Asthma and of the European Position Paper on Sinusitis and Nasal Polyposis. He has also served on the boards of the European Academy of Allergy & Clinical Immunology and the World Allergy Organization and as president of the German Society for Allergology and Clinical Immunology (DGAKI, 2007-2010) and as vice president (2011-2016). He is currently an editor for The Journal of Allergy and Clinical Immunology.

Christopher Brightling

MD, PhD, MBBS, FCCP, Professor
Institute for Lung Health

University of Leicester, England

Prof. Christopher Brightling is a National Institute for Health Research (NIHR) senior investigator, director of the Institute for Lung Health at the University of Leicester, respiratory theme lead for the Leicester NIHR Biomedical Research Centre, and honorary consultant respiratory physician. He is coordinator for the European Union consortium AirPROM, the Medical Research Council (MRC)/Association of the British Pharmaceutical Industry chronic obstructive pulmonary disease (COPD) consortium (COPDMAP), and the MRC Molecular Pathology Node EMBER. He is the founding director of the European Respiratory Society (ERS) Clinical Research Collaborations and chair-elect of the ERS Science Council.

A well-respected expert in the immunopathogenesis of airway diseases, particularly asthma, chronic cough, and COPD, Prof. Brightling is currently working on several projects, including understanding the interactions between mast cells and airway smooth muscle cells in the development of the asthmatic phenotype and migration and remodeling of airway smooth muscle in asthma and COPD.

Prof. Brightling has published more than 360 peer-reviewed articles and has an h-index of 93 (Google Scholar). He is associate editor of the prestigious CHEST journal and has contributed to updates for the American College of Chest Physicians’ Cough Guidelines, the British Thoracic Society Difficult Asthma Guidelines, and the American Thoracic Society/European Respiratory Society Severe Asthma Task Force.

William W. Busse

MD, Professor
Section of Allergy, Pulmonary, and Critical Care Medicine University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin, USA

“ADVENT is a cutting-edge educational program that explores and integrates the latest findings on type 2 inflammation across asthma and atopic dermatitis with a patient-centered approach towards both understanding and more effectively treating patients”

Prof. William W. Busse is a graduate of the University of Wisconsin and University of Wisconsin Medical School. Following an internship at Cincinnati General Hospital, he completed a residency in internal medicine and fellowship in allergy and immunology at the University of Wisconsin under the mentorship of Dr Charles E. Reed. Prof. Busse has been on the faculty at the University of Wisconsin Medical School since 1974. He has served as head of the Allergy and Clinical Immunology Section (1978-2004) and as the George R. and Elaine Love Professor and Chair of Medicine (2005-2009). He is a diplomate of the American Board of Internal Medicine and the American Board of Allergy and Clinical Immunology.

Prof. Busse’s research has focused on the mechanism of asthma, with particular interest in eosinophilic inflammation and rhinovirus-induced asthma, for which he has had long-standing National Institutes of Health (NIH) support, as well as in lung-brain interactions in asthma. He is principal investigator for the NIH/National Institute of Allergy and Infectious Diseases Inner-City Asthma Consortium, which is funded to study immune-based therapy for asthma in inner-city children, and for Asthmatic Inflammation and Neurocircuitry Activation, a research project (R01) funded by the National Heart, Lung, and Blood Institute.

Prof. Busse was a director on the American Board of Allergy and Immunology (1989- 1995). He was on the Advisory Council, National Institutes of Health, National Heart, Lung, and Blood Institute (1996-2000); a member of the Expert Panel on the Guidelines for the Diagnosis and Management of Asthma (1989, 2002); and a member of the Board of External Experts, National Heart, Lung, and Blood Institute (2006-2018). From 1994 to 2004, he was a member of the American Academy of Allergy, Asthma & Immunology (AAAAI) Board of Directors and served as president of the AAAAI in 2000-2001.

Prof. Busse is co-editor of the book Allergy: Principles and Practice and Asthma and Rhinitis. He was associate editor of the American Journal of Respiratory and Critical Care Medicine (1997-1998) and the Journal of Allergy and Clinical Immunology (2002-2005). In 2001, he was elected to the Association of American Physicians. Dr Busse received the Folkert Belzer Lifetime Achievement Award in 2004, the American Thoracic Society Award for Scientific Accomplishments in 2005, the Citation Award for Achievement from the University of Wisconsin School of Medicine and Public Health in 2008, and the American Thoracic Society Foundation Breathing for Life Award in 2014.

Giorgio Walter Canonica

MD, PhD, Professor
Humanitas University
Allergist and Pulmonologist
Humanitas Research Hospital
Milan, Italy

Prof. Giorgio Walter Canonica is professor of respiratory medicine at Humanitas University and director of the Personalized Medicine Asthma and Allergy Center at Humanitas Research Hospital in Milan, Italy.

Prof. Canonica first specialized in pulmonary diseases after receiving his medical degree from the University of Genoa, Italy. He then specialized in allergy and clinical immunology at Florence University, Italy. He subsequently conducted clinical immunology and allergology research at several European and US universities and institutes, such as the Biomedical Center of Uppsala University, Sweden, and the Medical University of South Carolina, USA. Since returning to the University of Genoa in 1995, Prof. Canonica has held a number of academic positions, including director of the Specialty School of Allergy and Clinical Immunology, director of the Specialty School of Pulmonary Diseases, and chairman of the Department of Medical Specialties (University Hospital San Martino, Genoa, Italy).

Prof. Canonica is a board member of ARIA (Allergic Rhinitis and Its Impact on Asthma) and helped develop its guidelines. He has been president of WAO (World Allergy Organization) and of Interasma–Global Asthma Association and is currently vice president of REG (Respiratory Effectiveness Group) and chair of the European Academy of Allergy and Clinical Immunology Methodology Committee. In addition, he is a steering committee member of SANI (Severe Asthma Network Italy).

H index, 102; Citations, >52.000; Peer-Reviewed Papers, >750

Kenneth R. Chapman

MD, MSc, FRCPC, FACP, FERS, Professor
University of Toronto
Director, Asthma and Airway Centre
University Health Network
Toronto, Canada

Prof. Chapman is director of the Asthma and Airway Centre of the University Health Network, president of the Canadian Network for Respiratory Care, and director of the Canadian Registry for Alpha-1 Antitrypsin Deficiency. A graduate of the University of Toronto and a former member of the faculty at Case Western Reserve University in Cincinnati, Ohio, USA, he is now a Professor of Medicine at the University of Toronto.

Prof. Chapman is an internationally respected researcher in the fields of asthma, chronic obstructive pulmonary disease (COPD), and airway diseases, and his publications have appeared in The New England Journal of Medicine and The Lancet, among other journals. The titles of his more than 600 publications range from “Emergency Medical Services for Outdoor Rock Music Festivals” to “The Effect of Posture on Thoracoabdominal Movements During Progressive Hyperoxic Hypercapnia in Conscious Man.” With more the 15,000 citations to his work, he is in the top 1% of cited medical researchers.

Prof. Chapman chaired Canada’s first consensus conference to establish Canadian guidelines for the management of COPD. He is the inaugural holder of the CIHR-GSK Research Chair in Respiratory Health Care Delivery at the University Health Network and was one of 5 Canadian respiratory physicians awarded a fellowship by the European Society in its inaugural year.

Jonathan Corren

David Geffen School of Medicine
University of California, Los Angeles, USA

Dr Jonathan Corren has been a faculty member of the Departments of Medicine and Pediatrics at the David Geffen School of Medicine of the University of California, Los Angeles (UCLA) since 1991 and is actively involved in allergy and immunology education at the university. He is also medical director of a private practice in allergy/immunology and research director of a clinical research site that focuses on severe asthma, chronic rhinosinusitis, allergy immunotherapy, immunodeficiencies, and allergic skin diseases. He is currently project chair for a multicenter trial evaluating the immunologic and clinical effects of allergen-specific immunotherapy combined with an inhibitor of thymic stromal lymphopoietin. He is also a consultant regarding clinical study design with multiple pharmaceutical companies, including AstraZeneca, Genentech, Novartis, Regeneron, and Sanofi. He previously served as director of the Allergy/Immunology Fellowship Program, chief of Clinical Services in Allergy/Immunology, and cohead of the Nasal and Sinus Disease Center at UCLA.

Dr Corren received a BA in biology from UCLA and a medical degree from UC San Diego. He completed an internship in internal medicine at the University of Southern California/Los Angeles County Medical Center, a residency in internal medicine at the UC Davis Medical Center, and a fellowship in allergy/immunology at the National Jewish Center for Immunology and Respiratory Medicine (Denver, Colorado), followed by an appointment at the center as an instructor in medicine and research scientist. His research papers regarding the use of biologic medications in severe asthma have been published in The New England Journal of Medicine, The Lancet, The Journal of Allergy and Clinical Immunology, and CHEST. He is a fellow of the American Academy of Allergy, Asthma & Immunology.

Zuzana Diamant

MD, PhD, Professor
Skåne University Hospital
Lund, Sweden

Dr Diamant is a pulmonologist and clinical pharmacologist and is currently an affiliate professor of asthma and allergy research at Skåne University Hospital in Lund, Sweden, and an honorary affiliate in the Department of Respiratory Medicine at Charles University and Thomayer Hospital in Prague, Czech Republic. She lives in the Netherlands, where she is affiliated with the Department of Clinical Pharmacy and Pharmacology at the University Medical Center of Groningen. Apart from her academic assignments, she acts as research director of the respiratory and allergy section at QPS-NL in Groningen, where she set up a phase I/II respiratory unit in 2012. Dr Diamant currently serves (2017–2019) as chair of the Asthma Section of the European Academy of Allergy and Clinical Immunology (EAACI). She is actively involved in several EAACI and European Respiratory Society initiatives, including serving on the Scientific Program Committee of the annual EAACI congress and as congress chair of both the Master Class on Biologicals (2018, Prague, Czech Republic) and the International Severe Asthma Forum (2018, Madrid, Spain), respectively and on several task forces that create position papers.

Dr Diamant has worked for more than 27 years in clinical and translational asthma and allergy research, with a focus on biomarkers and sampling methods and their applicability for disease phenotyping/endotyping, pathophysiologic mechanisms, clinical asthma models and targeted drug interventions. Furthermore, she serves on several scientific advisory boards and is involved in teaching and supervising PhD students and postdocs. She has coauthored over 110 peer-reviewed articles (original research, reviews, expert opinions, books) and serves on the editorial boards of several scientific journals in the fields of respiratory medicine, allergy, and pulmonary pharmacology.

Christian Domingo Ribas

Senior Consultant Medical Specialist, Pulmonology Service
Parc Taulí Health Corporation (CSPT), Sabadell (Barcelona)
Professor, Department of Medicine, Autonomous University of Barcelona, Spain

Dr Christian Domingo Ribas received his degree in medicine and surgery in 1984 from the Autonomous University of Barcelona (UAB). He earned his doctorate of medicine degree in 1991. His residency in pulmonology was completed at the Germans Trias i Pujol University Hospital (HUGTiP) in Badalona (Barcelona). He completed his training as a pulmonologist at the Cardiopulmonary Transplant Unit of Methodist Hospital of Houston, Texas (United States), and in the Intensive Care Unit of Hôpital de la Croix-Rousse in Lyon (France). In 2002, he obtained a master’s degree in health economics and health management from Pompeu Fabra University in Barcelona.

After completing his residency, Dr Domingo worked as an assistant physician in the HUGTiP Intensive Care Unit. In 1992, he moved to Parc Taulí University Health Corporation (CSUPT) in Sabadell. He was a professor in the Department of Anatomy and Physiology of the International University of Catalonia (2002-2009) and an associate professor in the Department of Medicine of UAB (2003-2013). He has been a member of the Gerson Lehrman Group’s Council of Healthcare since 2004. He is also currently a senior consultant medical specialist at the Pulmonology Service of the Parc Taulí University Health Corporation (CSUPT) and a full professor in the Department of Medicine at UAB.

Dr Domingo is a member of the Catalan (SOCAP), Spanish (SEPAR), and European (ERS) societies of pulmonology and a member of SEPAR’s commission responsible for drafting the regulations for the study and management of chronic cough as well as the prescription of monoclonal antibodies for bronchial asthma. He has organized the following scientific events: the Pneumological Conference in 2009, the 2nd International Conference on Drug Discovery and Therapy (ICDDT) in Dubai (2010), the First International Symposium on Cough in Clinical Practice (2015), the Barcelona Cough Conference (Second International Symposium on Cough in Clinical Practice, Barcelona, 2017), and the Barcelona Cough Conference of 2019.

Dr Domingo has supervised 10 doctoral theses and has published 137 papers in medical journals, 350 abstracts, and 19 book chapters, and is the editor of 1 book and 3 e-books. He is also the editor-in-chief of The Open Respiratory Medicine Journal. He has contributed to obtaining more than 1 million euros for scholarships and studies. In recent years, his main area of research has been severe asthma and, more recently, chronic cough.

Monica Kraft

MD, Professor
Chair, Department of Medicine
University of Arizona College of Medicine–Tucson
Robert and Irene Flinn Endowed Chair of Medicine
Tucson, Arizona, USA

Dr Monica Kraft is chair of the Department of Medicine at the University of Arizona (UA) College of Medicine–Tucson, where she is also a professor of medicine and the Robert and Irene Flinn Endowed Chair in Medicine. Prior to that, she was a professor of medicine, chief of the Division of the Pulmonary, Allergy, and Critical Care (PACC) Medicine, and director of the Duke Asthma, Allergy, and Airway Center (DAAAC) at Duke University Medical Center in Durham, North Carolina.

Dr Kraft earned her MD degree at the University of California, San Francisco. She completed her residency at Harbor-UCLA Medical Center, where she was also chief resident. She completed her fellowship in PACC Medicine at the University of Colorado Health Sciences Center in Boulder and joined the faculty as director of the Carl and Hazel Felt Laboratory for Adult Asthma Research and medical director of the Pulmonary Physiology Unit at National Jewish Health (1995-2004). She joined Duke University to create/direct the DAAAC in 2004.

Besides patient care and teaching, she has published extensively. Her research interests include the mechanisms of innate immune dysfunction, inflammation and airway remodeling in asthma, as well as evaluation of personalized/precision approaches to asthma therapy through clinical trials. Her work has been continuously funded by the National Institutes of Health and the American Lung Association for over 20 years and she is currently a member of the Advisory Council of the National Heart, Lung, and Blood Institute. She received the Presidential Early Career Award for Scientists and Engineers, awarded by President Bill Clinton at the White House, in 2000. She served as president of the American Thoracic Society in 2012-2013.

Ian Pavord

Professor of Respiratory Medicine
University of Oxford
Oxford, England

Prof. Ian Pavord is professor of respiratory medicine at the University of Oxford, where he is also professorial fellow of St Edmund Hall and honorary consultant physician at the Oxford University Hospitals. He was a consultant physician at the Institute for Lung Health, Glenfield Hospital, Leicester, England, from 1995 and honorary professor of medicine from 2005 to 2013.

Prof. Pavord’s research interests focus on the clinical aspects of inflammatory airway diseases. He has identified a number of clinically important phenotypes and biomarkers of inflammatory airway disease and has pioneered the use of noninvasive methods of measuring airway inflammation in the assessment of these conditions. He has also played a lead role in the clinical development of 3 of the most promising new treatments for severe airway disease.

Prof. Pavord was elected as a National Institute for Health Research senior investigator in 2011 and 2014, as an inaugural fellow of the European Respiratory Society (ERS) in 2014, and as a fellow of the Academy of Medical Sciences in 2015. He is also a member of the Congregation at the University of Oxford. Professor Pavord was co-editor of Thorax from 2010 to 2015, chief medical officer of Asthma UK from 2008 to 2014, and associate editor of the American Journal of Respiratory and Critical Care Medicine from 2005 to 2010. He has been associate editor of the European Respiratory Journal since 2016. Professor Pavord chaired the 2017 Lancet Commission on asthma and received the 2016 ERS Gold Medal for his research. He is the author of over 400 publications and has an h-index of 101.

Michael E. Wechsler

Director, NJH Cohen Family Asthma Institute
Professor of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO

Prof. Michael E. Wechsler is director of the National Jewish Health (NJH) Cohen Family Asthma Institute and professor of medicine in the Division of Pulmonary, Critical Care and Sleep Medicine at NJH in Denver, CO.

Prof. Wechsler’s research is focused on clinical and translational asthma, with emphasis on clinical trials in asthma, novel asthma therapies, bronchial thermoplasty, asthma pharmacogenomics, and management of eosinophilic granulomatosis with polyangiitis (Churg-Strauss Syndrome, CSS). He has led studies on novel biologic agents for asthma and related diseases, including benralizumab, dupilumab, mepolizumab, reslizumab, and tezepelumab. He has published more than 185 peer-reviewed manuscripts on asthma, CSS, and eosinophilic lung diseases.

Prof. Wechsler is a member of the Steering Committee and site principal investigator of the National Institutes of Health (NIH)–sponsored Asthma Clinical Research Network (now called AsthmaNet), a multicenter asthma clinical trials consortium, and of the Precision Intervention in Severe/Exacerbating Asthma (PrecISE) network. A member of The American Society for Clinical Investigation, he has participated on many different task forces related to the study of eosinophilic lung diseases that were sponsored by the NIH, the US Food and Drug Administration, the European Respiratory Society, and the International Eosinophil Society. He has served as associate editor of the journal Allergy and on the editorial board of the European Journal of Clinical Investigation.

Prof. Wechsler received AB and MMSc degrees from Harvard University in Boston, MA, and an MD degree from McGill University in Montreal, Canada. He completed medical training at Beth Israel Hospital in Boston as part of the Harvard Combined Pulmonary and Critical Care Fellowship Training Program.

MAT-US-2023022 V1 Exp Date 11/18/2022

Welcome to the ADVENT program website

ADVENT is a medical education program by Sanofi Genzyme and Regeneron. This website is intended only for health care professionals in the US only.


ADVENT is a global medical education program by Sanofi Genzyme and Regeneron and is only intended for healthcare providers.

You are leaving the ADVENT program website

Sanofi Genzyme does not review or control the content of non–Sanofi Genzyme websites, and this hyperlink does not constitute an endorsement by Sanofi Genzyme of the site’s content. Sanofi Genzyme’s privacy procedures do not apply to the owners of a non–Sanofi Genzyme website.